Outcomes of transsphenoidal surgery in prolactinomas: Improvement of hormonal control in dopamine agonist-resistant patients

European Journal of Endocrinology

Volumn 166, Issue 5, 2012, Pages 779-786

  Primeau, Vanessa ^a   Raftopoulos, Christian ^a   Maiter, Dominique ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; QUINAGOLIDE;

ADULT; ARTICLE; CANCER RELAPSE; COHORT ANALYSIS; CYTOREDUCTIVE SURGERY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEMALE; HORMONAL REGULATION; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RECURRENCE RISK; RETROSPECTIVE STUDY; THERAPY EFFECT; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT OUTCOME; TUMOR REGRESSION;

ADOLESCENT; ADULT; COHORT STUDIES; DOPAMINE AGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RETROSPECTIVE STUDIES; SPHENOID BONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862073167     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-1000     Document Type: Article

References (37)

1. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA & Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. Journal of Clinical Endocrinology and Metabolism 2006 91 4769-4775. (doi:10.1210/jc.2006-1668)
2. Fernandez A, Karavitaki N & Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical Endocrinology 2010 72 377-382. (doi:10.1111/j.1365-2265.2009.03667.x)
3. Raappana A, Koivukangas J, Ebeling T & Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. Journal of Clinical Endocrinology and Metabolism 2010 95 4268-4275. (doi:10.1210/jc.2010-0537)
4. Schlechte JA. Clinical practice. Prolactinoma. New England Journal of Medicine 2003 349 2035-2041. (doi:10.1056/NEJMcp025334)
5. Molitch ME. Prolactinoma. In Pituitary, 2nd edn, pp 119-171. Ed S Melmed. Malden, MA, USA, Blackwell Science, Inc., 2002.
6. Delgrange E, Trouillas J, Maiter D, Donckier J & Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism 1997 82 2102-2107. (doi:10.1210/jc.82.7.2102)
7. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA & Wass JA. Diagnosis and treatment of hyperpro-lactinemia: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2011 95 4268-4275. (doi: 10.1210/jc.2010-1692)
8. Gillam MP, Molitch ME, Lombardi G & Colao A. Advances in the treatment of prolactinomas. Endocrine Reviews 2006 27 485-534. (doi:10.1210/er.2005-9998)
9. Webster J. Clinical management of prolactinomas. Baillière's Clinical Endocrinology and Metabolism 1999 13 395-408. (doi:10.1053/beem.1999. 0030)
10. Schade R, Andersohn F, Suissa S, Haverkamp W & Garde E. Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine 2007 356 29-38. (doi:10.1056/NEJMoa062222)
11. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S & Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine 2007 356 39-46. (doi:10.1056/NEJMoa054830)
12. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L & Beckers A. Cabergoline and the risk of valvular lesions in endocrine disease. European Journal of Endocrinology 2008 159 1-5. (doi:10.1530/EJE-08-0213)
13. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G & Serri O. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009 12 153-157. (doi:10.1007/s11102-008-0134-2)
14. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G & Lombardi G. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. Journal of Clinical Endocrinology and Metabolism 2008 93 3777-3784. (doi:10.1210/jc.2007-1403)
15. Ambermoon P, Carter A, Hall WD, Dissanayaka NN & O'Sullivan JD. Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction 2011 106 283-293. (doi:10.1111/j.1360-0443.2010.03218.x)
16. Barns Neurauter MP, Rickards H & Cavanna AE. The prevalence and clinical characteristics of pathological gambling in Parkinson's disease: an evidence-based review. Functional Neurology 2010 25 9-13.
17. Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch F & Buchfelder M. Operative treatment of prolactinomas: indications and results in current consecutive series of 212 patients. European Journal of Endocrinology 2008 158 11-18. (doi:10.1530/EJE-07-0248)
18. Amar AP, Couldwell WT, Chen JC & Weiss M. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. Journal of Neurosurgery 2002 97 307-314. (doi:10.3171/jns.2002.97.2.0307)
19. Losa M, Mortini P, Barzaghi R, Gioia L & Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. Journal of Clinical Endocrinology and Metabolism 2002 87 3180-3186. (doi:10.1210/jc.87.7.3180)
20. Hamilton DK, Vance ML, Boulos PT & Laws ER. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 2005 8 53-60. (doi:10.1007/s11102- 005-5086-1)
21. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J & Trouillas J. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a postoperative follow-up. Journal of Clinical Endocrinology and Metabolism 2010 95 1708-1716. (doi:10.1210/jc.2009-1191)
22. Babey M, Sahli R, Vajtai I, Andres RH & Seiler RW. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary 2011 14 220-230. (doi:10.1007/s11102-010-0283-y)
23. Qu X, Wang M, Wang G, Han T, Mou C, Han L, Jiang M, Qu Y, Zhang M, Pang Q & Xu G. Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. European Journal of Endocrinology 2011 164 499-504. (doi:10.1530/EJE-10-0961)
24. Menucci M, Quiñones-Hinojosa A, Burger P & Salvatori R. Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 2011 14 68-74. (doi:10.1007/s11102-010-0261-4)
25. Molitch ME. Dopamine resistance of prolactinomas. Pituitary 2003 6 19-27. (doi:10.1023/A:1026225625897)
26. Delgrange E, Daems T, Verhelst J, Abs R & Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. European Journal of Endocrinology 2009 160 747-752. (doi:10.1530/EJE-09-0012)
27. Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB & Wilson CB. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 1999 44 254-261. (doi:10.1097/00006123- 199902000-00006)
28. Webster J, Page MD, Bevan JS, Richards SH, Douglas-Jones AG & Scanlon MF. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests. Clinical Endocrinology 1992 36 35-44. (doi:10.1111/j.1365-2265.1992.tb02900.x)
29. Serri O, Rasio E, Beauregard H, Hardy J & Somma M. Recurrence of hyperprolactinaemia after selective adenomectomy in women with prolactinomas. New England Journal of Medicine 1983 309 280-283. (doi:10.1056/ NEJM198308043090505)
30. Parl FF, Cruz VE, Cobb CA, Bradley CA & Aleshire SL. Late recurrence of surgically removed prolactinomas. Cancer 1986 57 2422-2426. (doi:10.1002/1097-0142(19860615)57:12<2422::AID-CNCR2820571229>3.0.CO;2-B)
31. Schlechte JA, Sherman BM, Chapler FK & VanGilder J. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1986 62 1296-1301. (doi:10.1210/jcem-62-6-1296)
32. Massoud F, Serri O, Hardy J, Somma M & Beauregard H. Transsphenoidal adenomectomy for microprolactinomas: 10-20 years of follow-up. Surgical Neurology 1996 45 341-346. (doi:10.1016/0090-3019(95)00430-0)
33. Reddy R, Cudlip S, Byrne JV, Karavitaki N & Wass JA. Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma? European Journal of Endocrinology 2011 165 739-744. (doi:10.1530/EJE-11-0566)
34. Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D & Chanson P. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. European Journal of Endocrinology 2010 163 193-200. (doi:10.1530/EJE-10-0255)
35. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G & Cozzi R. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2006 91 85-92. (doi:10.1210/jc.2005-1208)
36. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P & Beckers A. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. European Journal of Endocrinology 2005 152 61-66. (doi:10.1530/eje.1.01824)
37. Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C & Enjalbert A. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994 60 314-322. (doi:10.1159/000126764)